Investor Relations

Press Releases

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015

Read More

Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2

Read More

Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development

Read More

Advaxis's President and Chief Executive Officer Daniel J. O'Connor Receives 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey

Read More

Advaxis Provides 2015 Half-Year Review and Outlook

Read More

Advaxis Selected for Inclusion in Russell Global and Russell 3000® Indexes

Read More

Advaxis to Hold Business Update Conference Call on June 25, 2015

Read More

Advaxis Submits Special Protocol Assessment Request to FDA for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer

Read More

Advaxis's Cancer Immunotherapy Delays Progression of HER2+ Canine Osteosarcoma

Read More

Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated Early Stage Cervical Cancer

Read More